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ABSTRACT The human immunodeﬁciency virus type 1 (HIV-1) integrase (IN) is an essential enzyme in the life cycle of the
virus and is an attractive target for the development of new drugs useful in acquired immunodeﬁciency syndrome multidrug
therapy. Starting from the crystal structure of the 5CITEP inhibitor bound to the active site in the catalytic domain of the HIV-1
IN, two different molecular dynamics simulations in water have been carried out. In the ﬁrst simulation the wild-type IN was
used, whereas in the second one the double mutation T66I/M154I, described to lead to drug resistance, was introduced in the
protein. Compelling differences have been observed in these two structures during analyses of the molecular dynamics
trajectories, particularly in the inhibitor binding modes and in the conformational ﬂexibility of the loop (residues 138–149) located
near the three catalytic residues in the active site (Asp64, Asp116, Glu152). Because the conformational ﬂexibility of this region
is important for efﬁcient biological activity and its behavior is quite different in the two models, we suggest a hypothetical
mechanism for the inhibition and drug resistance of HIV-1 IN. These results can be useful for the rational design of more potent
and selective integrase inhibitors and may allow for the design of inhibitors that will be more robust against known resistance
mutations.
INTRODUCTION
Human immunodeﬁciency virus type 1 (HIV-1) is the etio-
logical agent of the acquired immunodeﬁciency syndrome
(AIDS). Enzymes essential for the replication cycle of this
virus, such as reverse transcriptase (RT), protease (PR), and
integrase (IN) are important targets for the development of
anti-AIDS drugs. Although effective inhibitors have been
developed against RT and PR with several of them now
being marketed as anti-AIDS agents, no drug active against
HIV-1 integrase has been approved by the U.S. Food and
Drug Administration. Because viral genome integration is es-
sential to the replication of the retroviruses and, unlike PR
and RT, IN has no known functional analog in human cells,
the development of drugs able to inhibit one of the various
steps involved in integration should be very useful in AIDS
multidrug therapy (De Clercq, 2000).
The HIV-1 IN enzyme, which belongs to the superfamily
of polynucleotidyltransferases, inserts a double-stranded
DNA copy of the viral RNA genome into the chromosomes
of an infected cell through two separate reactions (Engelman
et al., 1991). In the ﬁrst hydrolytic step, termed ‘‘39-pro-
cessing,’’ IN removes two nucleotides from each viral cDNA
end adjacent to a conserved 39-CA sequence leading to the
formation of a new recessed 39-CA-OH end. In the second
reaction, called ‘‘strand transfer’’ or ‘‘transesteriﬁcation,’’
the two newly processed 39-viral DNA ends are inserted
into opposite strands across a ﬁve basepair stretch of host
target DNA. Two separate active sites (i.e., two distinct IN
proteins) are involved in the simultaneous double strand
transfer. The product of this step is a gapped intermediate
product in which the 59-phosphate ends of the viral DNA are
no longer linked to the 39-OH ends of the host DNA. Both
reactions show a direct nucleophilic attack by a hydroxyl
group. IN uses an activated water molecule as the
nucleophile in the 39-end processing, while in the strand
transfer the newly exposed 39-CA-OH group from the viral
DNA is the nucleophile that attacks the host DNA backbone.
The integration process is completed by cleavage of the un-
paired dinucleotides from the 59-ends of the viral DNA and
repair of the gaps between the viral and target DNA. Al-
though IN may be involved in these repair reactions, it is
not necessary because the host cell already has the machinery
to carry out such processes. In vitro, integrase can also carry
out an apparent reversal of the strand transfer reaction,
referred to as ‘‘disintegration’’ (Chow et al., 1992). For the
integration reaction, no source of energy (e.g., no ATP) is
needed and only divalent cations such as Mn2þ or Mg2þ are
required for the catalytic activity (Asante-Appiah and
Skalka, 1999; Wlodawer, 1999).
Retroviral IN is a 32-kDa enzyme (288 residues) encoded
by the pol gene and is composed of one polypeptide chain
that folds into three distinct functional domains: the N-ter-
minal domain (residues 1–50), the catalytic core domain
(residues 50–212), and the C-terminal domain (residues
212–288). The amino-terminal domain contains a conserved
‘‘HH-CC’’ motif that binds a Zn2þ ion and promotes enzyme
multimerization (Zheng et al., 1996; Lee et al., 1997). The
catalytic domain is composed of a mixed a-helix and b-sheet
motif and contains an absolutely conserved D,D-35-E motif
characterized by three acidic residues, Asp64, Asp116, and
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Glu152; the last two residues are separated by 35 amino acids
(Engelman and Craigie, 1992; Kulkosky et al., 1992; Polard
and Chandler, 1995). The C-terminal domain has been
shown to have a nonspeciﬁc but strong DNA binding activity
similar to that of the full-length IN (Engelman et al., 1994;
Vink et al., 1993). All three domains bind DNA, and each
isolated domain forms a homodimer in solution. Even
though all three domains are required for full catalytic
activity, site-directed mutagenesis experiments have shown
that the central core domain is sufﬁcient to promote a reverse
integration reaction in vitro, known as disintegration, indi-
cating that this region contains the enzymatic catalytic center
(Chow et al., 1992; Bushman et al., 1993). The structures
of the three separate domains have been solved by x-ray
crystallography or NMR spectroscopy (Dyda et al., 1994;
Bujacz et al., 1996; Maignan et al., 1998; Goldgur et al.,
1998; Greenwald et al., 1999; Eijkelenboom et al., 1995;
Eijkelenboom et al., 1999; Lodi et al., 1995; Cai et al., 1997;
1998). The ﬁrst crystal structure of the catalytic core domain
did not reveal any bound metal ion in the active site; and a 13-
residue loop and helix bounded by residues 140 and 154,
which includes the third conserved amino acid Glu152, was
not resolved (Dyda et al., 1994).
Later, complete structures of this IN domain have been
reported, but the previously unresolved loop/helix close to
the active center is still not well deﬁned because of high
temperature factors, suggesting that this region is either par-
ticularly ﬂexible or disordered in the crystal. Cross-link-
ing studies of IN with DNA revealed that residues in this
region (139–152) could be cross-linked to DNA close to the
reactive phosphate (i.e., the scissile bond), placing the loop
near the substrate during the reaction (Heuer and Brown,
1997; Esposito and Craigie, 1998). The loop may hold the
DNA substrates in proper position while the active site
carries out the integration reaction. In addition, mutation
studies have shown that Tyr143 is involved in the integration
reactions by hydrogen-bonding thereby stabilizing and
directing the nucleophiles for attack (van Gent et al., 1993;
Esposito and Craigie, 1998; Beese and Steitz, 1991; Chen
et al., 2000). Unfortunately, the active conformation adopted
by the surface loop during the integration reaction is
unknown; however, it is evident that its mobility is correlated
with the catalytic activity. Single and double loop hinge
mutations (G140A, G149A, G140A/G149A) have reduced
or abolished activity (Greenwald et al., 1999). X-ray struc-
tures are available for some of these loop hinge mutants
(Greenwald et al., 1999).
Beese and Steitz proposed that, by analogy to the 39-59
exonuclease of Escherichia coli DNA polymerase I, the
three conserved acidic residues in the retroviral integrases
coordinate two metal ion cofactors, forming a template for
DNA binding and catalysis (Beese and Steitz, 1991). How-
ever, the HIV-1 IN structures available to date contain only
a single divalent metal ion bound to the catalytic core do-
main, while the location of the binding site for the second
metal ion is not yet deﬁned, leading to the thought that
the second metal cofactor may bind together with a DNA
substrate. On the other hand, structures of the avian sarcoma
virus (ASV) IN catalytic domain are available with one or
two noncatalytic divalent metal ions bound (Bujacz et al.,
1997).
Recently, the ﬁrst HIV-1 IN two-domain structure (PDB
code 1EX4, residues 52–288) has been solved by x-ray
crystallography (Chen et al., 2000). Two different crystal
structures of a ligand bound to the HIV-1 IN have been
reported. The ﬁrst HIV-1 IN inhibitor complex (PDB code
1QS4) was solved by Goldgur et al. (Goldgur et al., 1999)
and shows a novel Shionogi integrase inhibitor 5CITEP in
complex with the HIV-1 IN catalytic domain. Furthermore,
in 2001 a small-molecule binding site was identiﬁed at the
dimer interface of the HIV-1 IN enzyme (PDB code 1HYV
and 1HYZ) (Molteni et al., 2001).
However, the fully bioactive structure of the HIV-1 IN
in vivo is still unknown. Numerous studies suggest that the
smallest multimer with full catalytic activity is a tetramer or
an octamer (Cai et al., 1997; Heuer and Brown, 1998). In
fact, the full nuclear preintegration complex contains 50–100
copies of integrase along with structural proteins and double-
stranded DNA (Bukrinsky et al., 1992; Bowerman et al.,
1989). Site-directed mutagenesis and photo-crosslinking
studies have identiﬁed several residues near the active site
that are critical for binding viral DNA (Heuer and Brown,
1997; Esposito and Craigie, 1998; Jenkins et al., 1997).
Recently, Hazuda et al. have presented a new class of
integrase inhibitors with a diketo acid functionality (Hazuda
et al., 2000). Among them, L-731,988 and L-708,906 are
two of the most active molecules and exhibit the unique
ability to inhibit the strand transfer reaction. Individual and
combined mutations in HIV-1 IN at Thr66, Met153, and
Met154 have been reported to confer some degree of re-
sistance to one or more inhibitors.
Using the x-ray structure of the 5CITEP inhibitor bound
to the IN catalytic core domain as the starting point, we
have carried out two different molecular dynamics (MD)
simulations. In the ﬁrst simulation, the wild-type IN was
used for our studies, while in the second one the double
mutation T66I/M154I was introduced in the protein. The
5CITEP inhibitor was present in the structures of both
simulations.
The aims of the present work were to 1), understand
the relationship between ligand-IN complex formation and
functional response; 2), obtain evidence of the role of the
loop close to the active site in the catalytic activity; 3),
hypothesize the molecular mechanisms for HIV-1 IN drug
resistance; and ﬁnally 4), obtain information for receptor-
based drug design.
We observed substantial differences between these two
structures during the MD simulations, particularly in the
inhibitor binding mode and in the structure and dynamics of
the surface loop located near the three catalytic residues in
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the active site (Asp64, Asp116, Glu152). On this basis, our
ongoing work is the rational design and testing of new HIV-1
IN inhibitors.
COMPUTATIONAL METHODS
Structures
Protein
The x-ray crystallographic structure of the HIV-1 IN catalytic core domain
(subunit A, residues 56–140, 145–209) complexed with the Shionogi
inhibitor 5CITEP (PDB code 1QS4) (Goldgur et al., 1999) was used as the
initial structure in both simulations. This crystal structure contains oneMg2þ
coordinated by Asp64 and Asp116 and has some unresolved residues in the
ﬂexible loop Gly140–Gly149 adjacent to the active site, connecting helices a4
and a5. The unresolved region (residues 141–144) was manually completed
based on the conformation of the homologous loop in the crystal structure of
the uncomplexed core domain of HIV-1 integrase 1BIS (Goldgur et al.,
1998). Residue Tyr143 in the loop, which has been proposed to be involved
in the catalytic mechanism, was modeled based on its conformation in mo-
nomer B of 1QS4, in which it is pointed toward the active site. All hy-
drogens were added to the proteins according to previous electrostatically
based pKa predictions (Lins et al., 1999) using the UHBD program (Madura
et al., 1995), where no unusual amino acid ionization states were predicted
(i.e., Asp1, Glu1, Argþ1, His0, Lysþ1, C-Term1, N-Termþ1).
The region including residues 139–146 was minimized using 100 steps of
steepest-descent minimization employing a distance-dependent dielectric
and the Discover/CVFF force ﬁeld in the InsightII package (InsightII, 2000).
Residues Thr66 and Met154 were each computationally replaced with Ile to
obtain the double mutant system using the InsightII/Biopolymer module.
The starting orientations of the new Ile side chains (Fig. 1) were chosen after
consideration of the physical environment of the two residues, trying to
initially avoid steric clashes.
Ligand
The starting structure of 5CITEP was that present in the complex with the
HIV-1 IN (PDB code 1QS4). The semiempirical PM3 method was used to
calculate the partial atomic charges of the inhibitor (Table 1).
All of the force ﬁeld parameters necessary to describe the bonded and
nonbonded interactions involving the ligand atoms were kindly provided by
Ni et al., 2001. The augmented (i.e., with hydrogens or mutations) wild-type
and T66I/M154I IN proteins both complexed with 5CITEP, were used as
initial structures for our MD simulations.
Molecular dynamics simulations
Two independent 1.75 ns MD simulations with an equilibration phase of 80
ps each were carried out using the parallel NWChem v.3.3.1 program
(Anchell et al., 1999) with the 1995 version of the all-atom AMBER force
ﬁeld (Cornell et al, 1995). The molecular trajectory for the two systems
generated by the molecular dynamics simulations were analyzed using the
Analysis module in NWChem v.4.0 (Harrison et al., 2000) and the DeCipher
module in the InsightII package.
The same MD simulation protocol was applied for both simulations. For
our studies we used the NPT ensemble (pressure ¼ 1.025 3 105 Pa) with
explicit solvent and periodic boundary conditions. The integration of the
equations of motion was carried out using the leap-frog algorithm (Hockney
and Eastwood, 1981); all bonds involving hydrogen atoms were constrained
to their equilibrium values by means of the SHAKE algorithm (Ryckaert
et al., 1977). During the equilibration phase, the velocities were reassigned
every 0.5 ps according to a Maxwell-Boltzmann distribution. A short-range
spherical cutoff of 10 A˚ was used for all nonbonded interactions while the
smooth particle-mesh Ewald (PME) method (Essmann et al., 1995) was
applied to have an adequate treatment of the long-range electrostatic
energies and forces.
The complexes were immersed in a cubic box (72 3 72 3 72 A˚) of
extended simple point charge (SPC/E) water molecules (Berendsen et al.,
1987). Water molecules that were within 2.6 A˚ of any nonhydrogen atom of
the protein were deleted. The solvated systems were neutralized by addition
of two chloride ions (whose positions were randomly chosen and were
initially far away from the molecular surface of the protein) and then relaxed
FIGURE 1 Orientation of residues 66 and 154 (a) in the crystal structure
and (b) in the initial model of T66I/M154I HIV-1 IN complex.
TABLE 1 Atom types and charges for 5CITEP
Atom name Atom type Charge
C1 CA 0.087
C2 CA 0.058
C3 CN 0.246
C4 CB 0.030
C5 CA 0.022
C6 CA 0.120
N7 NA 0.422
C8 CW 0.188
C9 C* 0.229
C10 C 0.407
C11 CM 0.245
C12 C 0.306
C13 CC 0.040
N14 NB 0.141
N15 NB 0.046
N16 NB 0.015
N17 NB 0.200
O18 O 0.347
O19 OH 0.176
CL20 XC 0.075
H1 HA 0.117
H2 HA 0.109
H3 HA 0.128
H4 H 0.069
H5 H4 0.151
H6 HC 0.147
H7 HO 0.259
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by performing 100 steps of steepest descent followed by 1000 steps of
conjugate gradient energy minimization to remove the strain in the initial
structure before the MD trajectory.
For the simulation with the wild-type IN/5CITEP complex, the entire
system consisted of 2403 solute atoms (protein, inhibitor, one Mg2þ, and
two Cl counter ions) and 33,999 solvent atoms, whereas for the double
mutant IN/5CITEP system the number of solute and solvent atoms were
2410 and 33,998, respectively.
MD simulation studies consist of equilibration and production phases. In
the ﬁrst stage of equilibration, the solute (protein, counter ions, Mg2þ, and
ligand) was ﬁxed and the solvent (water molecules) was equilibrated for 30
ps of molecular dynamics at 298 K using an integral time step of 1 fs. Then,
the solvent was constrained while the protein was heated from 50 K to 298 K
in increments of 50 K, using intervals of 5 ps each with a 1 fs time step. The
full (i.e., solute and solvent) systems were subjected to MD at 298 K using
a 1 fs time step over 80 ps, during which time the systems achieved stability.
After the equilibration period, the production phase was run for 1.75 ns
for each system, using an integral time step of 2 fs with a constant
temperature of 298 K kept constant by weak coupling to a heat bath, and
separate relaxation times of 0.4 and 0.1 ps were used for the solvent and
solute, respectively. The coordinates of the system were saved every 0.1 ps
during the simulations for later analyses.
Essential dynamics analyses
Essential dynamics (ED) analyses were performed for both 1.75 ns MD
trajectories. Each frame of the trajectory was superimposed onto the
equilibrated geometry to remove rotational and translational movements and
to isolate only the internal motions of the system. ED analyses were focused
on the movement of the 154 Ca atoms of the protein. The Cartesian co-
ordinates for the atoms result in 462 dimensional displacement vectors.
The 4623 462 covariance matrix was constructed based on the coordinates
from the MD trajectories and then diagonalized to obtain its eigenvalues and
eigenvectors. Movements in the essential subspace were projected along the
most important eigenvectors from the analyses. These overall ED analyses
were performed using the WHATIF program (Vriend, 1990).
RESULTS AND DISCUSSION
We have performed two MD simulations, one of the wild-
type and one of the double mutant T66I/M154I IN, both
complexed with the 5CITEP inhibitor. At the beginning of
this work, 5CITEP was the only crystal structure of an in-
hibitor bound to the active site (PDB code 1QS4), so we
decided to use this ligand for our studies to have a good
starting model. The integrase inhibitor 5CITEP, 1-(5-
chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenone
(Fig. 2), is one of a group of Shionogi integrase inhibitors
with 50% inhibitory concentrations (IC50) of 2.3 6 0.1 mM
and 2.16 0.1 mM by multiple plate integration assay (MIA)
and multiple plate preincubation assay (MPA), respectively
(Goldgur et al., 1999).
The inhibitor forms a dimer with another molecule of
5CITEP at a crystallographic dimer interface, so the binding
site of this inhibitor in the crystal is rather unlikely to
resemble a physiologically relevant binding conﬁguration, as
also recently reported in computational studies of 5CITEP
optimized binding modes in the absence of the crystallo-
graphic environment (Sotriffer et al., 2000).
Therefore, the 5CITEP/IN complex has been subjected to
1.75 ns of MD in explicit solvent with the aim of gaining
information about the bioactive conformation of the ligand
within the catalytic site and the mechanism of inhibition.
On the other hand, to understand the effect of drug
resistant mutations on the inhibitor binding mode, we
performed another MD simulation with the Ile modeled at
residues 66 and 154. Even though this double mutation was
reported to confer resistance to the diketo acid inhibitors
(Hazuda et al., 2000), it is important to note that 5CITEP is
also a diketo acid inhibitor and is an analog of L-731,988
(Fig. 2), where the carboxylic group is replaced with one of
its typical bioisosteres, e.g., the tetrazole ring. Considering
this observation, it is reasonable to think that the same
mutations conferring resistance to L-731,988 should have
a similar effect on 5CITEP.
Analysis of the dynamics trajectories
Thermodynamic properties such as temperature and energies
were monitored during the MD simulations and all con-
verged to stable values. The results presented here refer to
the starting structures (i.e., after the equilibration of 80 ps)
and average structures for the two MD simulations of wild-
type and T66I/M154I inhibitor complexes.
Protein folding of the wild-type and
T66I/M154I IN
Using the DSSP module (Kabsch and Sander, 1983)
implemented in the ICMlite v.2.7 software (Abagyan et al.,
1994), secondary structural analyses were performed for the
two average structures over the whole simulation period, and
their folds are shown in Fig. 3. Additionally, the HBPLUS
software (McDonald and Thornton, 1994) has been used
to calculate and compare the hydrogen-bonds in the two
proteins. To qualify an interaction as a hydrogen-bond, we
have used the default geometric criterion as deﬁned in the
program: the donor-acceptor heavy atom distance had to
be shorter than 3.9 A˚, the maximum distance between
a hydrogen atom donor and an acceptor of 2.5 A˚, and the
donor-hydrogen-acceptor angle had to be larger than 908.
We compared the fold of our models with the x-ray
structure of the catalytic core domain used as the starting
point, which consists of a central ﬁve-stranded b-sheet with
six surrounding a-helices, the same as the crystal forms
FIGURE 2 5CITEP and L-731,988 HIV-1 IN inhibitors.
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obtained to date of the HIV-1 IN catalytic domain. Some
notable structural changes were found in our complexes and
detailed analyses were performed. In Table 2 we summarize
the characteristics of the secondary structure in both the
modeled and x-ray crystal structures.
In the wild-type complex (Fig. 3 a), the major difference
from previously reported unliganded core domain structures
is with the lack of helix a2, originally composed of residues
Ser119 through Thr122. In fact, after the ﬁrst 200 ps this short
helix is no longer present because hydrogen-bonds between
Thr97-Asn120 and Gly118-Phe121 were broken in the early
stages of the dynamics simulation. Moreover, in this model
the side chains of Asn120 and Phe121 are not involved in s-p
interactions, because the amine group from Asn120 is now
located at ;4.0 A˚ from the plane of the phenyl group, as
compared with a distance of ;3.3 A˚ in the x-ray and T66I/
M154I structures (Maignan et al., 1998). Interestingly, the
double mutant model (Fig. 3 b) has instead the same a-b fold
of the initial structure.
The secondary structural analyses reveal a signiﬁcant
difference between the two complexes in the area between
residues 136 and 166, which includes the ﬂexible loop close
to the active center. In the x-ray structure as well as in the
wild-type model, b5 consists of four residues (136–139)
whereas in the double mutant it is shorter; after the ﬁrst 300
ps of the production phase for the double mutant Glu138 and
Phe139 are no longer in a bstrand conformation.
On the other hand, in the wild-type system the long
antiparallel helix a4, that forms a part of the active site and
contains the catalytic carboxylate Glu152, is deﬁned by
residues 149–165, which is different from T66I/M154I that
shows a4 from residues 150 to 166, as in the latest published
apoenzyme structures. As a result of these different ar-
rangements, the loop in the two models has a different
length, consisting of 9 (140–148) and 12 residues (138–149)
in the wild-type and double mutant complexes, respectively.
Furthermore, the native enzyme contains two additional
hydrogen-bonds involving residues in the loop (Gln62-Ser147
and Asn144-Gln146), which are not present in the double
mutant complex.
This initial information already suggested that in the
native protein complex with the drug, the loop near the
catalytic residues might be more constrained and less ﬂexible
than in the double mutant enzyme complex with the in-
hibitor. A slight difference was moreover observed in the
length of b4 that is one residue longer (Thr115) in the wild-
type complex with respect to the starting structure and the
T66I/M154I complex.
Overall perturbative changes in the two models
The root-mean-square deviations (RMSD) of the Ca atoms
with respect to the starting and average coordinates over the
two MD simulations are plotted in Fig. 4. It can be seen
clearly that after the ﬁrst 500 ps the wild-type IN is fairly
stable during the entire remaining period of MD simulation,
with an RMSD value with respect to the starting structure of
;1.3 A˚. The T66I/M154I system shows a larger ﬂexibility,
and the RMSD increases from 0.6 to 2.3 A˚ over the ﬁrst 900
ps of the whole trajectory. After this period, the system
stabilizes to around 1.9 A˚. Using the average structures as the
FIGURE 3 Ribbon diagram of the (a) wild-type and (b) T66I/M154I
HIV-1 IN complexes from average structures over the entire simulations.
The ﬁgures were prepared using the program MOLMOL (Koradi et al.,
1996).
TABLE 2 Characteristics of the secondary structure in all three IN complexes
Complex Sheet 1 Sheet 2 Sheet 3 Helix 1 Sheet 4 Helix 2 Helix 3 Sheet 5 Helix 4 Helix 5 Helix 6
Wild-type IN 60–68 71–78 83–89 94–107 112–115 — 124–132 136–139 149–165 172–185 196–208
T66I/M154I IN 60–68 71–78 83–88 94–107 112–114 119–122 124–132 136–137 150–166 172–183 196–206
X-ray structure 60–68 71–78 83–89 94–105 112–114 119–122 124–132 136–138 150–166 172–185 196–206
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reference, the mean RMSD value is 1.3 A˚ for the wild-type
and 2.0 A˚ for the double mutant complexes, respectively.
The two models exhibit different dynamical behavior; the
wild-type displays conformational rigidity higher than that
of the native enzyme. Fig. 4 is helpful in conveying the dy-
namics of the overall structures; however, we were also
interested in seeing which parts of the protein were more
ﬂexible and affected by the double resistance mutation, so
we monitored the root-mean-square ﬂuctuations of the Ca
atoms (i.e., somewhat analogous to crystallographic B-fac-
tors) for each residue during MD simulations. Fig. 5
compares the calculated B-factors with the experimental
ones from the x-ray structure.
Our data indicate that the larger ﬂuctuations are con-
centrated in two regions corresponding to residues 138–149
and 187–195, which are ﬂexible loops on the surface of the
protein as reported in uncomplexed core domain structures.
The second loop, 187–195, exhibits almost the same be-
havior in both simulations except for residue Gly189, which
is hydrogen-bonded to Tyr194 for the entire length of the
simulation of the double mutant complex, whereas this in-
teraction is never present in the wild-type dynamics study.
In any event, this region is far away from the active site,
so we focused our attention on the loop containing residues
138–149, because this region has been found to adopt several
different conformations in previous structures, and its mo-
bility appears to be correlated with IN catalytic activity.
Moreover, our secondary structural analyses showed that
the length of the loop is not constant in the two complexes,
being shorter in the wild-type system (residues 140–148)
in comparison to the double mutant T66I/M154I (residues
138–149).
It is obvious from the plot in Fig. 5 that the loop did not
undergo the same conformational changes in the two sim-
ulations. The T66I/M154I complex shows larger ﬂuctuations
for the residues 138–149 than in the wild-type model indi-
cating that the double mutation affected the dynamics of this
region.
This result seemed extremely important to us. Previous
molecular, Brownian, and essential dynamics studies of the
uncomplexed wild-type IN (Lins et al., 1999; Weber et al.,
1998; Lins et al., 2000) showed that the same regions (138–
150 and 185–195) were the most ﬂexible parts of the HIV-1
protein. The calculated B-factors for the uncomplexed
enzyme simulation (Lins et al., 2000) are higher compared
with those of the wild-type IN-5CITEP complex, but similar
to the values obtained from the T66I/M154I complex
simulation.
This result may explain a portion of the mechanism of
inhibition by 5CITEP, i.e., by decreasing the mobility of the
active site loop. Of course, 5CITEP bound to the wild-type
IN physically blocks substrate access to the active site. It also
suggests that the mechanism by which the double mutation
leads to inhibitor resistance is by restoring the loop to wild-
type ﬂexibility, apparently necessary for catalytic activity.
Furthermore, the double mutant complex shows a slightly
greater structural ﬂuctuation of residues Gly82, Ser119,
Thr122, Gly163, and Asp167 compared to the wild-type com-
plex. In addition, the inhibitor in the double mutant com-
plex moves deeper into the binding pocket, apparently no
longer blocking substrate binding nor tying up the cat-
alytic residues.
Dynamic behavior of the active site
We have monitored the distance between the ﬁxed center of
the catalytic site and the carboxyl groups of Asp64, Asp116,
and Glu152 as a function of simulation time to gain insights
into the conformational changes of the three conserved res-
idues. The center of the catalytic site was deﬁned using a
pseudoatom based on the center of mass of all nonhy-
drogen atoms in the three catalytic residues Asp64, Asp116,
and Glu152. The average distances between Asp64, Asp116,
FIGURE 4 Root-mean-square deviation
(RMSD) of the Ca atoms for the (a) wild-
type and (b) T66I/M154I IN complexes as
a function of simulation time.
FIGURE 5 Plots of the experimental and calculated B-factors of the Ca
atoms as a function of residue number along the chain. The positions of
residues 66 and 154 are marked in the original crystal structure.
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and Glu152 to the geometric center of the active site are 2.64
A˚, 5.48 A˚, and 7.76 A˚ for the wild-type and 3.12 A˚, 5.17 A˚,
and 5.18 A˚ for the double mutant, respectively. The
ﬂuctuations of the Asp64 and Asp116 are in the same range
in both complexes, so we can conclude that these residues
are not signiﬁcantly inﬂuenced by the mutations. On the
other hand, T66I/M154I has an effect on residue Glu152.
Examination of the average structures revealed that the side
chain of Glu152 faces the general direction of the two cat-
alytic aspartates in the double mutant complex, whereas in
the wild-type complex this catalytic residue points away from
the two other active carboxylates.
In the wild-type complex the backbone of Glu152 is
engaged in hydrogen-bonds with the O of Gln148 and the N
of Lys156 over the entire simulation. In the double mutant
system, the interaction with Lys156 is preserved, while that
with Gln148 is replaced by Gly149. In both systems the side
chain atoms of Glu152 are not involved in any intramolecular
contacts, but are involved in hydrogen-bonds with solvent
molecules. However, in the wild-type complex, atom OE2 of
Glu152 maintains a water-mediated interaction to the keto
oxygen of 5CITEP.
As we already mentioned, in all HIV-1 IN structures
reported to date, only a single bound metal ion is found at the
active site, which may suggest that the second ion, most
likely between the ﬁrst and third catalytic residues (Asp64
and Glu152) as seen in ASV IN structures, binds only in the
presence of a DNA substrate.
In both models the magnesium ion is complexed in an
octahedral fashion by Asp64, Asp116, and four water mol-
ecules, a conﬁguration already observed in native crystal
forms. In the wild-type complex these coordinated water
molecules are involved in hydrogen-bonds with Asp64,
Asp116, Cys65, and Asn117, whereas the last interaction is not
present in the double mutant.
We also found that in both average complex structures, the
conserved Glu152 did not create a proper metal-binding site
for the second cofactor, most likely because of the presence
of the inhibitor. In fact, in our models the distance between
the carboxylate carbons of Asp64 and Glu152 is 9.98 A˚ in the
wild-type and 8.40 A˚ in the double mutant, compared with a
distance of 8.00 A˚ in the model coming from an MD sim-
ulation of the catalytic domain of the HIV-1 IN containing
two Mg2þ ions (Lins et al., 2000) and 7.20 A˚ in the x-ray
structure of the catalytic domain of ASV IN with two
divalent metal ions in the active site (PDB code 1VSH)
(Bujacz et al., 1997).
Conformational changes of the loop close
to the active site
It was evident from the results of the secondary structural
analyses and the RMS ﬂuctuations for Ca atoms in the wild-
type and T66I/M154I simulations that the loop residues 138–
149 showed conformational differences between the two
complexes. This region therefore needed to be carefully
explored in an effort to understand the inﬂuence of its local
motion on the catalytic mechanism of the HIV-1 IN enzyme.
The RMSD of the loop (Ca atoms) clearly shows the
behavior of this region over the entire length of the simu-
lations (Fig. 6). The ﬁgure indicates that the conformation of
the loop is stable during the course of the MD trajectory of
the wild-type complex, showing an average RMSD below
1.5 A˚. On the contrary, during the ﬁrst 900 ps of the double
mutant T66I/M154I IN complex simulation, the RMSD
increased from 0.6 to 8.7 A˚. This large conformational
change started at ;300 ps when Glu138 and Phe139 were no
longer in a b-strand conformation and the loop began to
widen. From 900 ps to 1350 ps the loop did undergo some
structural adjustments, and in the last 400 ps the RMSD
ﬂuctuated between 4.6 and 6.8 A˚.
These loop transitions were accompanied by changes in
hydrogen-bonding. In particular, the principal determinants
of the different backbone dynamics in the two systems might
be residues Gln62 and Gln148. We think that the hydrogen-
bonds involving these two residues in the wild-type complex
are the main cause of the rigidity of the catalytic loop, an-
choring it to other residues in the protein. Residue Gln148 is
at or just beyond the end of helix a4 that contains Glu152,
whereas Gln62 is on the opposite side of the active site,
two residues away from the catalytic Asp64. In fact, the
hydrogen-bonds between Gln62–Gln148, Gln148–Glu152, and
Gln62–Ser147 are almost always present during the dynamics
simulation of the wild-type complex. Furthermore, Gln62 has
a strategic position in holding the backbone loop in nearly
ﬁxed conformation, because it seems to occupy the center of
the catalytic site and works as an anchor controlling the
mobility of the region 138–149.
In the double mutant enzyme, all of these interactions
were disrupted after the ﬁrst 300 ps of the simulation.
Consequently, Gln62 participates in a hydrogen-bond with
Ile151, whereas Gln148 exhibits only water-bridging inter-
actions. However, further analyses were performed with the
aim of better comprehending the signiﬁcance of the loop
motions in both systems. The distance between the Ca atoms
of Gly140 and Gln148, which can be taken as a measure of the
FIGURE 6 RMSD over the trajectory of the Ca atoms of the loop 138–
149 taking as the reference frame the starting structure.
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width of the active loop, is 11.35 A˚ and 12.76 A˚ in the
average structures of the wild-type and double mutant com-
plexes, respectively.
In the wild-type complex, a hydrogen-bond interaction
was formed in the early stage of the dynamics simulation
between Gly140 and Thr115 and remains throughout the dy-
namics run, preventing Gly140 from moving. At the begin-
ningof theT66I/M154Icomplexproductionrun, the backbone
oxygen of Gly140 maintained a hydrogen-bond to NE2 of
Gln148; however, at around 300 ps this interaction was lost
and Gly140 was no longer involved in any hydrogen-bonds
over the remainder of the simulation time. Gly140 was there-
fore not ‘‘constrained’’ so its backbone was permitted to
move, resulting in more loop motion and a wider active site.
The time evolution of the angle between the planes
deﬁned for the three catalytic residues and the loop 138–149
over the entire simulation period helped us to reveal the real
movements of this region and to quantify howmuch it moves
away or toward the active center.
The wild-type IN maintains an angle value of ;758 in-
dicating that once more the loop in this system has reduced
mobility. On the contrary, in the T66I/M154I complex this
angle is initially 758 and during the ﬁrst 250 ps of the sim-
ulation it dramatically decreases to 208, showing that the loop
moves toward the catalytic site (after 1500 ps, the average
value is 278).
These results completely conﬁrmed our initial idea that the
double drug-resistant mutation restored high (i.e., uncom-
plexed wild-type) mobility in the catalytic loop whereas the
drug constrains the loop in the wild-type.
Role of Tyr143 in the catalytic activity
Tyr143 in the active site loop has been suggested to play
a secondary but important role in the catalytic activity of the
integrase (Esposito and Craigie, 1998; Chen et al., 2000;
Lins et al., 1999; Tsurutani et al., 2000), so we focused some
attention on this residue. Tyr143 is located in the disordered
loop near the catalytic site and, based on the proposed
mechanism for the integration process as being like the Tyr
in the 39-59 exonuclease activity of E. coli polymerase I
(Beese and Steitz, 1991), this residue might be involved in
the enzymatic activity by stabilizing and properly orienting
the nucleophile through a hydrogen-bond interaction, con-
sequently assisting the catalysis of the hydrolytic and
phosphoryl transfer reactions.
An important difference in the conformation and dynam-
ics of Tyr143 has been observed in the trajectory analyses
of the wild-type drug complex and double mutant drug
complex simulations. In the wild-type model, the distance
between atoms OE1 of Glu152 and the OH of Tyr143
increases during the ﬁrst 800 ps from 13 A˚ to ;21 A˚. So,
even though the backbone of the loop containing residues
138–149 is largely stable in the wild-type drug complex
simulation, the side chain of Tyr143 moves away from the
active site. Conversely, in the T66I/M154I complex, the loop
exhibits high mobility although Tyr143 does not move very
far from the starting point, maintaining an average distance
over the entire simulation of ;10.1 A˚. This compares well
with the average distance of 10.06 A˚ calculated for a 1 ns
MD simulation of the same model of the catalytic domain of
the wild-type IN without inhibitor (unpublished results). The
differences in the conformation of the loop and especially
with Tyr143 between the two models can easily be seen in
Fig. 7, where the average structures were superimposed by
their backbones.
Our observation that Tyr143 has been substantially de-
formed in the wild-type complex, where a lack of enzymatic
activity is seen, supports the hypothesis that its conformation
and mobility are important for the integration process and
that this residue might be a central player in the mechanism
of the integration process. In addition, mutation of Tyr143
was shown to affect the ratio between 39-processing and
strand transfer activities (van Gent et al., 1993).
Inhibitor binding mode
The interaction between HIV-1 IN and 5CITEP in the two
complexes as well as the inﬂuence of the inhibitor on the
structural and dynamical properties of the active site region
have been clariﬁed by analyzing the trajectory data obtained
from the MD simulations.
It is evident from the RMSD of all nonhydrogen atoms of
5CITEP (Fig. 8) that the inhibitor behaves quite differently
in the wild-type versus how it behaves in the resistant double
mutant, and that surprisingly its binding mode is more stable
in the double mutant model. In fact, in the T66I/M154I
simulation the inhibitor remains in the same conformation
during almost the entire simulation (average RMSD from
the initial structure is 1.1 A˚), whereas in the wild-type its
position did undergo substantial changes, up to a maximum
RMSD of 9.0 A˚ at 980 ps, stabilizing only in the latter part
of the trajectory (average RMSD is ;4.5 A˚). Other analyses
of the trajectory show that the inhibitor does not move in a
simple way. The distance between the center of the catalytic
FIGURE 7 Superimposed average structures from the MD simulations of
the wild-type (black) and double mutant (gray) IN.
Inhibitor Resistance in HIV-1 Integrase 1457
Biophysical Journal 84(3) 1450–1463
triad (D64, D116, and E152) and the center of the indole and
tetrazole rings of the ligand for the two models as a function
of the simulation time (Fig. 9) gave us some insights into the
differential behavior of the two portions of the ligand, even
though in both simulations the intramolecular hydrogen-
bond of the keto-enol group was preserved throughout the
dynamics runs. The binding mode of 5CITEP in the two
average structures is shown in Figs. 7 and 11.
Wild-type complex
The structure used as the starting point for the production run
showed that 5CITEP interacted through hydrogen-bonds
with Asp64, Cys65, Thr66, and Asn155.
During the ﬁrst 200 ps, the indole ring moves a little away
from the center of the active site, while the tetrazole portion
moves rapidly toward the catalytic triad; in particular, it
moves closer to Asp64 and Asn155. From 300 ps to ;500 ps
of simulation time, the hydrogen-bond involving 5CITEP
and Thr66 is gradually lost and the chloroindole ring, pos-
sibly due to steric interactions with Ile141, Tyr143, and Gln148,
starts to move away from the original binding site and toward
the solvent. Simultaneously, the keto-enol group moves
toward Gln148 while the tetrazole portion approaches Asn155.
Starting at 560 ps the tetrazole ring shifts the side chain of
Asn155 from its position (atom ND2 of Asn155 moves ;3.5
A˚) and slips into a pocket consisting of Asp64, Cys65, Thr66,
Val75, Ile151, Glu152, Asn155, and the magnesium ion with
its four coordinated water molecules. The inhibitor is at this
point almost perpendicular to the plane deﬁned by the three
catalytic residues, with the tetrazole portion buried in the
pocket, the keto-enol group toward Glu152, and the indole
ring solvent-exposed.
Between 500 ps and 1 ns of the dynamics run, occasional
hydrogen-bonds occur between 5CITEP and Asp64, Cys65,
Asn155, Gln148, and Ile151. It seems to us that because of
these forming and breaking bonds, the inhibitor oscillates up
and down within its binding site. At ;1100 ps, the indole
ring moves closer to Gln148 and Glu152, while Asn155 is
within hydrogen-bonding distance of the enol hydroxyl.
Except for the constant presence of the hydrogen-bond with
Cys65, the ligand does not show direct interactions with other
residues in the protein in the latter phase of the simulation.
According to x-ray analysis, the 5CITEP inhibitor is
hydrogen-bonded to several residues in the active site, such
as Thr66, Gln148, Asn155, Glu152, Lys156, and Lys159. As we
described earlier, this optimal hydrogen-bonding geometry
was lost thereafter due to competition with solvent mole-
cules. In fact, using the average structure it was observed that
the wild-type IN-5CITEP binding mode contains indirect
interactions via bound waters: the keto oxygen of 5CITEP
exhibits a solvent-mediated interaction to one of the
carboxylate oxygens of Glu152, while a bridge of two water
molecules is present between the nitrogen of the indole ring
of the ligand and the Mg2þ ion.
It should be noted that in our MD simulation of the wild-
type, the inhibitor adopted a completely different orientation
as compared to the x-ray structure and furthermore showed
a different binding site with respect to the ones presented
in previous computational docking studies (Sotriffer et al.,
2000). In fact, the authors reported two main binding
positions of the 5CITEP to the IN core domain. In the most
frequently occurring and most favorable result, the ligand
was found with the main molecular plane aligned ‘‘horizon-
tally’’ within the active site, whereas in our work the ligand
is perpendicular to the plane deﬁned by the three catalytic
residues. However, in both cases, the keto-enol oxygen
pointed toward Glu152 and Asn155, and the chloroindole is
FIGURE 8 RMSD from the initial structure for all nonhydrogen 5CITEP
atoms as a function of simulation time.
FIGURE 9 Time evolution of the distance between the ﬁxed center of the catalytic triad (D64, D116, and E152) and the center of the indole and tetrazole
rings of the ligand for the (a) wild-type and the (b) double mutant complexes.
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located in proximity to Gln148. The second result of the
docking was found less frequently, and the inhibitor showed
an ‘‘opposite’’ orientation with respect to the one we have
presented: the chlorine became completely buried, the keto-
enol oxygens are oriented toward the Asn155 amide, and the
indole NH remained solvent-exposed.
Double mutant complex
In T66I/M154I, both the indole and tetrazole portions are
nearly stable during the course of the MD trajectory, with an
average distance from the catalytic center of;5.6 and 3.0 A˚,
respectively. The inhibitor binding mode is therefore pre-
served along the entire dynamics simulation, and 5CITEP is
involved in hydrogen-bonding interactions with the protein
(a nitrogen atom of the tetrazole ring with a side chain
oxygen atom of Asp64 and the indole NH with the backbone
oxygen of His114). Furthermore, the keto-enol group exhibits
hydrogen-bonds only with solvent molecules. In this model,
5CITEP occupies a cleft that is formed by Gln62, Leu63,
Asp64, Ile66, His114, Thr115, Asp116, Glu138, Phe139, Ile141,
Tyr143, Ser147, Gln148, Ile151, Glu152, Asn155, and the metal
ion with one coordinated water molecule.
In particular, the chloroindole portion is oriented toward
Asn155, while the tetrazole ring lies between Asp116 and
Gln148. Furthermore, it is important to note that Tyr143 is
above the ligand, which does not interfere with the orien-
tation of this residue and also allows it to point toward
Glu152. However, in this double mutant system the ligand is
more deeply embedded in the protein than in the x-ray
structure of the wild-type.
So, in both of our molecular dynamics simulations, most
of the initial IN-5CITEP hydrogen-bonding interactions are
gradually lost and other interactions, such as van der Waals
interactions, appear to contribute largely to the stability of
the inhibitor in the two complexes.
Essential dynamics studies
To support our MD results, we have performed principal
component analyses (i.e., essential dynamics). In protein MD
simulations, many atomic ﬂuctuations occur, although few
represent correlated motions. In general, the correlated mo-
tions are less than 1% of all possible motions. Essential
dynamics (ED) is a method that can ﬁlter out all of the locally
conﬁned ﬂuctuations and vibrational motions in a macromo-
lecular system to focus on the few large and global structural
motions (Amadei et al., 1993).
By diagonalizing the covariance matrix, the anharmonic
and large-scale motions of the protein are isolated from
the much larger number of remaining, mostly harmonic and
small-scale motions. It has been established that the large-
scale anharmonic motions in the essential subspace are often
correlated to the vital functions of the protein.
To visualize the largest correlated motions of the proteins,
two projected structures representing the minimal and max-
imal amplitudes along the ﬁrst eigenvector were superim-
posed. It is worth noting that this ED analysis method shows
the entire range of the motion rather than the dynamic
ﬂexibility of the region, which can be shown by atomic
ﬂuctuation calculations.
The characteristic movements of the catalytic core
domains of the WT and the double mutant (T66I/M154I)
were compared by superimposing the structures, as dis-
played in Fig. 10, for wild-type (Fig. 10 a) and the double
mutant (Fig. 10 b). The signiﬁcant differences between the
two structures are in both loop regions, i.e., residues 138–
149 (Loop A) and residues 185–194 (Loop B). For quan-
titative comparison of the differences, the Ca-Ca distances
of each maximal and minimal structure were measured for
all 154 residues (Fig. 10 c). The plot clearly shows that the
amplitudes of the motions of both loops were signiﬁcantly
increased by the double mutation.
It has been previously reported that the ﬂexibility of the
active site loop is important for the enzymatic activity
(Greenwald et al., 1999). These ED results suggest that the
range of the loop motion may be correlated to the enzymatic
activity. The double mutant has inhibitor resistance. Al-
though it is not known whether the inhibitor can still bind
to the doubly mutated enzyme, our simulations suggest that
even if it does bind, it should not interfere with substrate
binding (because it does not block the active site) and wild-
type loop dynamics exist in the double mutant even with
drug bound. At this point we hypothesize that the double
mutant regains the dynamical characteristics of the active site
loop of the wild-type even with the inhibitor bound. We
therefore propose that dynamical ﬂexibility of the loop is
critical for enzymatic activity and the double inhibitor
resistant mutant recovers activity by exhibiting wild-type
loop ﬂexibility, even in the presence of bound inhibitor.
Effect of the double mutation
The differential behavior of the loop and the ligand in the
two systems needs to be explained in the context of the
mutation of residues Thr66 and Met154. At the beginning of
the wild-type simulation, Thr66 made hydrogen-bonds with
Ile73, Asn155, His67, and the inhibitor. After the ﬁrst 500 ps of
dynamics simulation, the ligand-Thr66 interaction is broken
and replaced by a hydrogen-bond with Lys159. At around
800 ps, the Thr66-Asn155 hydrogen-bond is also disrupted
and only the interactions with Ile73 and Lys159 remain for the
remainder of the trajectory.
Conversely, for the entire simulation of the double mutant
model, Ile66 was involved in the only conserved hydrogen-
bonding interaction with the backbone of Ile73. Because
Thr66 was mutated to Ile66 in the double mutant system, it
was evident that during the simulation, the inhibitor could
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not move into the same binding pocket available in the wild-
type enzyme (Fig. 11 a) because the side chain of Ile66
occupied the center of that pocket (Fig. 11 b).
During the entire simulation of the double mutant
complex, Ile154 makes hydrogen-bonds involving Val150,
Leu158, and Glu157; on the other hand, in the wild-type
trajectory all of these interactions except the last one are
conserved.
However, even if the interactions involving Ile154 are
almost the same in both trajectories, the bulkier side chain of
Ile154 seems to inﬂuence the conformation of neighboring
residues. One of these residues is Glu152 which i), is a cat-
alytic residue and is able to orient itself toward the other two
active carboxylates even when the 5CITEP inhibitor is pre-
sent in the double mutant and ii), stabilizes the inhibitor
binding position in the wild-type complex through a water-
bridge. Furthermore, Ile154 belongs to the helix a4 that, as
we have shown, exhibits a different average length in the two
systems (i.e., wild-type enzyme plus inhibitor and double
mutant enzyme plus inhibitor).
FIGURE 10 The largest correlated motions for the HIV
IN catalytic core domains of (a) wild-type and (b) double
mutant with a bound inhibitor, 5CITEP. For each ﬁgure,
two protein trace structures from the maximal and minimal
projections along the largest eigenvector were super-
imposed to show the largest correlated motions (maximum
in black and minimum in gray). The two major moving
loops, designated as Loop A and Loop B, are highlighted
in thick black. Each structure was slightly rotated to show
each loop structure clearly. For quantitative comparisons
of the two structures, the 154 Ca-Ca distances of each
maximal and minimal structure were measured (c).
FIGURE 11 Comparison of the average structures from the (a) wild-type and the (b) double mutant T66I/M154I IN complex MD simulations.
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Hypothetical mechanism for inhibition and
drug resistance of IN
All of these results and observations led us to hypothesize
a mechanism for the inhibition and drug resistance of IN.
Recent DNA cross-linking studies with Rous sarcoma virus
(RSV) IN suggested a model in which at least four mo-
nomers are required for concerted integration of two viral
DNA ends into a target DNA (Yang et al., 2000). The cat-
alytic activity is carried out only by two of the subunits,
while the other ones help to position the substrate and
stabilize the complex. Using as a template the structure of the
two-domain (residues 49–286) RSV IN x-ray structure
modeled with both viral cDNA ends and target DNA (kindly
provided by F. D. Bushman), we have made hypotheses
about the function of the inhibitor and double resistance
mutation. In fact, the wild-type and double mutant average
structures were superimposed with the RSV IN crystal form
via their Ca atoms.
Fig. 12 shows, for both systems, the three conserved
residues Asp64, Asp116, and Glu152; the Mg2þ metal ion; the
backbone of the catalytic loop with the Tyr143 side chain; the
recessed 39-OH group of a viral DNA end; the host cell
chromosomal DNA phosphate group; and the orientation of
the inhibitor.
The presence of the 5CITEP inhibitor in the wild-type
enzyme could be important for stabilizing a nonfunctional
conformation of the HIV-1 IN enzyme (Fig. 12 a). In fact,
the inhibitor might affect the conformation of the surface
loop near the active site that adopts a more constrained
conformation with the side chain of Tyr143 pointing in the
opposite direction of the catalytic center and of both DNA
ends. Furthermore, in the wild-type complex, 5CITEP adopts
a position that might inhibit the formation of the IN-DNA
complex by occupying the DNA substrate-binding site and,
considering the two-metal mechanism for the IN catalysis,
might prevent the binding of the second divalent cation to its
likely site located between residues Asp64 and Glu152.
When the Thr66 and Met154 residues are mutated to Ile,
HIV-1 IN might be able to assume a functional conformation
with Tyr143 in the ﬂexible loop and Glu152 pointing toward
the active site (Fig. 12 b). This model seems to be an accept-
able snapshot of the integration process, showing that in the
double mutant the inhibitor position does not completely
disturb the catalytic activity of the IN enzyme.
CONCLUSION
We have reported results herein of two 1.75 ns molecular
dynamics (MD) simulations of the wild-type IN and the
double mutant T66I/M154I both complexed with the
5CITEP inhibitor. Detailed analyses of structural perturba-
tions in the enzyme-inhibitor complexes indicate that the two
proteins display a distinct dynamical behavior. Major and
signiﬁcant structural differences were found at the catalytic
residue Glu152, the ﬂexible loop 138–149 close to the active
site, and in the mode in which the inhibitor binds to the active
site of the enzyme.
In fact, the binding of 5CITEP to the wild-type IN caused
several conformational changes especially in the loop 138–
149 near the catalytic center, which achieved a rigid
backbone conﬁguration. Simultaneously, a dramatic confor-
mational change of the side chain of Tyr143 brought this
residue far away from the active site. The structure adopted
by the constrained loop appears to represent a nonfunctional
conformation of the HIV-1 IN enzyme.
Conversely, the MD simulation of the double resistance
mutant IN (T66I/M154I) complex displayed a different
conformational transition in the loop 138–149 and a high
FIGURE 12 Hypothetical proposed mechanism for the HIV-1 IN inhibition (a) 5CITEP/wild-type IN complex, and (b) drug resistant 5CITEP/T66I/M154I
IN complex, by MD studies.
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degree of mobility in this region. The orientation of the
Tyr143 within the catalytic loop is quite different in this
model, pointing completely toward the active site.
In addition, the binding mode of the inhibitor is quite
different in the two systems. In the wild-type complex the
ligand has the tetrazole ring oriented approximately toward
the pocket while the indole ring remains solvent-exposed; in
the T66I/M154I complex, the inhibitor kept the same
conﬁguration throughout the molecular dynamics simulation
and is more deeply buried in the active site than in the wild-
type complex.
This work has provided insights into the detailed
mechanism of action of the 5CITEP inhibitor and suggested
the mechanistic cause of IN inhibition and drug resistance.
Based on these results, our short-term aim is the design of
suitable selective ligands able to inhibit integrase function.
We are currently using snapshots of the structures taken
throughout the MD trajectories in docking studies of known
HIV-1 IN inhibitors and in the development of rigid and
dynamic (Carlson et al., 2000) pharmacophore models for
use in 3D database searching.
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